Is Europe Safe from the Myopia Epidemic? - Summary - MDSpire

Is Europe Safe from the Myopia Epidemic?

As global myopia rates soar, three landmark meta-analyses examine the European epidemiological landscape

  • By

  • Cristina Álvarez Peregrina

  • Miguel Ángel Sánchez-Tena

  • Pelsin Demir

  • Andrzej Grzybowski

  • May 5, 2026

  • 5 min

Share

Objective:

To assess the changing prevalence of myopia in Europe and its implications for public health and clinical practice, particularly in early detection and management.

Key Findings:
  • Overall prevalence of myopia in Europe is between 23.5% and 24.9%, with significant geographical disparities.
  • Adolescent myopia rates can reach nearly 50% in some cohorts, particularly in Southern Europe.
  • High myopia (≤-6.00D) affects over 3% of the European population, posing long-term health risks.
  • Measurement techniques significantly impact reported myopia prevalence, with cycloplegic studies showing lower rates compared to non-cycloplegic methods.
Interpretation:

Europe is experiencing a shift in myopia prevalence, influenced by modern lifestyle factors such as increased educational demands, urbanization, and reduced outdoor activity, which collectively heighten myopia risk.

Limitations:
  • Variability in measurement techniques may lead to overestimation of myopia prevalence, complicating public health responses.
  • Lack of standardized diagnostic protocols across EU member states.
Conclusion:

Europe is at a critical juncture regarding myopia management, necessitating standardized protocols and proactive management strategies to address the rising prevalence and mitigate future public health impacts.

Original Source(s)

Is Europe Safe from the Myopia Epidemic?

  • by Cristina Álvarez Peregrina, Miguel Ángel Sánchez-Tena, Pelsin Demir, Andrzej Grzybowski

  • May 5, 2026

Related Content

Current status of vision and refractive errors among children and adolescents in northeast Sichuan, China: a school-based cross-sectional study

The Myopia Control Kit

Thomas Aller, OD, provides in-depth overviews of each myopia management option—pharmacologic therapy, soft contact lenses, orthokeratology, spectacle lenses, and environmental and behavioral interventions—so clinicians can not only provide the right option to each patient, but also address the larger economic and societal burdens of myopia.

Multifocal Mythbusting

Concerns about chair time, adaptation issues, and inconsistent vision are rooted in outdated perceptions shaped by earlier generations of lenses and overshadow the many benefits that multifocal contact lenses can offer patients who have presbyopia.